ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      59,948.30
      1.21%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. AbbVie Inc (ABBV)

      7. AbbVie Inc (ABBV) News

      ABBV

      AbbVie (ABBV)

      AbbVie Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:ABBV
      DateTimeSourceHeadlineSymbolCompany
      01/05/20225:32AMTipRanksAbbVie Gets Breakthrough Therapy Designation for Lung Cancer TreatmentNYSE:ABBVAbbVie Inc
      01/04/20225:04PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
      01/04/20225:03PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
      01/04/20225:03PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
      01/04/20228:15AMPR Newswire (US)AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung CancerNYSE:ABBVAbbVie Inc
      01/04/20228:00AMPR Newswire (US)AbbVie to Present at the 40th Annual J.P. Morgan Healthcare ConferenceNYSE:ABBVAbbVie Inc
      12/30/20215:02PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
      12/30/202110:43AMTipRanksAbbVie Is Much More than HumiraNYSE:ABBVAbbVie Inc
      12/28/202112:53PMTipRanksAbbVie: Valuation, Debt, and Declining Margins Remain RisksNYSE:ABBVAbbVie Inc
      12/27/20214:35AMTipRanks2 Top-Rated Biotech Stocks for 2022NYSE:ABBVAbbVie Inc
      12/23/20215:02PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
      12/21/20215:29PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
      12/17/20215:02PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
      12/16/20215:03PMEdgar (US Regulatory)Current Report Filing (8-k)NYSE:ABBVAbbVie Inc
      12/16/20218:57AMPR Newswire (US)Allergan Aesthetics Completes Acquisition of SolitonNYSE:ABBVAbbVie Inc
      12/14/20216:18PMPR Newswire (US)RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic ArthritisNYSE:ABBVAbbVie Inc
      12/14/20215:02PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
      12/14/20212:25PMDow Jones NewsSoliton Up 12% as Nasdaq Alert Says Sale to AbbVie Is Scheduled to Close ThursdayNYSE:ABBVAbbVie Inc
      12/14/202112:35PMDow Jones NewsAbbVie on Track for Record High Close -- Data TalkNYSE:ABBVAbbVie Inc
      12/09/20219:00AMPR Newswire (US)VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry Near Vision (Presbyopia), is Now AvailableNYSE:ABBVAbbVie Inc
      12/08/20218:20PMTipRanksMizuho Securities Believes AbbVie (ABBV) Won’t Stop HereNYSE:ABBVAbbVie Inc
      12/08/20215:03PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
      12/08/202111:34AMTipRanksAbbVie Stock: Strong Dividend Growth and Reasonably ValuedNYSE:ABBVAbbVie Inc
      12/07/20214:17AMTipRanksLeerink Partners Believes AbbVie (ABBV) Still Has Room to GrowNYSE:ABBVAbbVie Inc
      12/06/20219:20AMDow Jones NewsAbbVie: Rinvoq Meets Key Endpoints in Phase 3 Crohn's Disease StudyNYSE:ABBVAbbVie Inc
      12/06/20218:30AMPR Newswire (US)Upadacitinib (RINVOQ®) Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's DiseaseNYSE:ABBVAbbVie Inc
      12/06/20217:25AMTipRanksAbbVie Updates RINVOQ Indications for the Treatment of RA in the U.S.NYSE:ABBVAbbVie Inc
      12/03/20214:15PMPR Newswire (US)AbbVie Provides Update on RINVOQ® (upadacitinib) for the Treatment of Rheumatoid Arthritis in the U.S.NYSE:ABBVAbbVie Inc
      11/30/20218:58AMDow Jones NewsAbbVie Submits Europe Application for Risankizumab for Crohn's DiseaseNYSE:ABBVAbbVie Inc
      11/30/20218:05AMPR Newswire (US)AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA)NYSE:ABBVAbbVie Inc
       Showing the most relevant articles for your search:NYSE:ABBV